Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Cosmet Investig Dermatol. 2009 Jul 23;2:111-28.

Biologics in the management of psoriasis.

Author information

  • 1Department of Dermatology, University Hospitals Case Medical Center, Cleveland, Ohio, USA.

Abstract

Psoriasis is a chronic inflammatory systemic disease for which there exist topical, ultraviolet, systemic, and biologic treatments. Biologic agents selectively interfere with the immune mechanisms responsible for psoriasis. Etanercept, infliximab, and adalimumab target tumor necrosis factor-alpha and have demonstrated efficacy in the treatment of psoriasis and psoriatic arthritis. Alefacept and efalizumab target T lymphocytes, are effective in the treatment of psoriasis, but are not approved for psoriatic arthritis. Finally, ustekinumab and ABT-874 target interleukin-12 and interleukin-23, and they have demonstrated efficacy in the treatment of psoriasis. The objective of this review is to present efficacy and safety data from randomized controlled trials of the biologic agents in the treatment of psoriasis.

KEYWORDS:

biologics; interleukin-12/23; psoriasis; tumor necrosis factor

PMID:
21436974
[PubMed]
PMCID:
PMC3047928
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk